> Detailanzeige
Lewis, Nathaniel M;
Murray, Nancy;
Adams, Katherine;
Surie, Diya;
Gaglani, Manjusha;
Ginde, Adit A;
McNeal, Tresa;
Ghamande, Shekhar;
Douin, David J;
Talbot, H Keipp;
Casey, Jonathan D;
Mohr, Nicholas M;
Zepeski, Anne;
Shapiro, Nathan I;
Gibbs, Kevin W;
Files, D Clark;
Hager, David N;
Ali, Harith;
Prekker, Matthew E;
Frosch, Anne E;
Exline, Matthew C;
Gong, Michelle N;
Mohamed, Amira;
Johnson, Nicholas J;
[...]
Absolute and Relative Vaccine Effectiveness of Primary and Booster Series of COVID-19 Vaccines (mRNA and Adenovirus Vector) Against COVID-19 Hospitalizations in the United States, December 2021–April 2022
Teilen
Literatur-
verwaltung
Direktlink
Zur
Merkliste
Lösche von
Merkliste
Per Email teilen
Auf Twitter teilen
Auf Facebook teilen
Per Whatsapp teilen
- Medientyp: E-Artikel
- Titel: Absolute and Relative Vaccine Effectiveness of Primary and Booster Series of COVID-19 Vaccines (mRNA and Adenovirus Vector) Against COVID-19 Hospitalizations in the United States, December 2021–April 2022
- Beteiligte: Lewis, Nathaniel M; Murray, Nancy; Adams, Katherine; Surie, Diya; Gaglani, Manjusha; Ginde, Adit A; McNeal, Tresa; Ghamande, Shekhar; Douin, David J; Talbot, H Keipp; Casey, Jonathan D; Mohr, Nicholas M; Zepeski, Anne; Shapiro, Nathan I; Gibbs, Kevin W; Files, D Clark; Hager, David N; Ali, Harith; Prekker, Matthew E; Frosch, Anne E; Exline, Matthew C; Gong, Michelle N; Mohamed, Amira; Johnson, Nicholas J; [...]
- Erschienen: Oxford University Press (OUP), 2023
- Erschienen in: Open Forum Infectious Diseases
- Sprache: Englisch
- DOI: 10.1093/ofid/ofac698
- ISSN: 2328-8957
- Schlagwörter: Infectious Diseases ; Oncology
- Entstehung:
- Anmerkungen:
- Beschreibung: <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background</jats:title> <jats:p>Coronavirus disease 2019 (COVID-19) vaccine effectiveness (VE) studies are increasingly reporting relative VE (rVE) comparing a primary series plus booster doses with a primary series only. Interpretation of rVE differs from traditional studies measuring absolute VE (aVE) of a vaccine regimen against an unvaccinated referent group. We estimated aVE and rVE against COVID-19 hospitalization in primary-series plus first-booster recipients of COVID-19 vaccines.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>Booster-eligible immunocompetent adults hospitalized at 21 medical centers in the United States during December 25, 2021–April 4, 2022 were included. In a test-negative design, logistic regression with case status as the outcome and completion of primary vaccine series or primary series plus 1 booster dose as the predictors, adjusted for potential confounders, were used to estimate aVE and rVE.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>A total of 2060 patients were analyzed, including 1104 COVID-19 cases and 956 controls. Relative VE against COVID-19 hospitalization in boosted mRNA vaccine recipients versus primary series only was 66% (95% confidence interval [CI], 55%–74%); aVE was 81% (95% CI, 75%–86%) for boosted versus 46% (95% CI, 30%–58%) for primary. For boosted Janssen vaccine recipients versus primary series, rVE was 49% (95% CI, −9% to 76%); aVE was 62% (95% CI, 33%–79%) for boosted versus 36% (95% CI, −4% to 60%) for primary.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions</jats:title> <jats:p>Vaccine booster doses increased protection against COVID-19 hospitalization compared with a primary series. Comparing rVE measures across studies can lead to flawed interpretations of the added value of a new vaccination regimen, whereas difference in aVE, when available, may be a more useful metric.</jats:p> </jats:sec>
- Zugangsstatus: Freier Zugang